CI-CAR-135

N/A

Report date: 2025/01/26 18:27:32

Base Information

Drug NameCI-CAR-135
Drug Alias NameFLT3 CARanti-FLT3 CAR T-cell therapy (City of Hope/Cytoimmune Therapeutics)RRV-FLT3-CAR-tCD19 transduced autologous T cells (City of Hope/Cytoimmune Therapeutics)CI-CAR-135
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 modulators
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytoImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytoImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A